Startseite › Multiples Myelom › North Carolina › Charlotte
Klinische Studien zu Multiples Myelom in Charlotte, NC
21 Studien zu Multiples Myelom suchen Teilnehmer an Standorten in und um Charlotte (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Teilnehmer gesuchtPhase 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Teilnehmer gesuchtPhase 1
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Teilnehmer gesuchtPhase 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Teilnehmer gesuchtPhase 4
- Levine Cancer Institute, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Teilnehmer gesuchtPhase 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Teilnehmer gesuchtPhase 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Teilnehmer gesuchtPhase 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Teilnehmer gesuchtPhase 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Teilnehmer gesuchtPhase 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Teilnehmer gesuchtPhase 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Levine Cancer Institute, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Atrium Health Levine Cancer, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Teilnehmer gesuchtPhase 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Teilnehmer gesuchtPhase 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Teilnehmer gesuchtPhase 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Levine Cancer Institute, Charlotte
Multiples Myelom-Studien in anderen Städten
- New York City, NY60 Studien
- Boston, MA42 Studien
- Atlanta, GA41 Studien
- Houston, TX38 Studien
- Durham, NC37 Studien
- Nashville, TN32 Studien
- Denver, CO27 Studien
- Rochester, MN24 Studien
- St. Louis, MO24 Studien
- Columbus, OH24 Studien
- Baldwin Park, CA23 Studien
- Chicago, IL22 Studien
Weitere Studien in Charlotte
- Krebs (alle Arten)27 Studien
- Brustkrebs22 Studien
- Nichtkleinzelliges Lungenkarzinom19 Studien
- Akute myeloische Leukämie16 Studien
- Adipositas16 Studien
- Übergewicht15 Studien
- Kolorektales Karzinom13 Studien
- Eierstockkrebs12 Studien
- Metastasierender Krebs11 Studien
- Herzinsuffizienz11 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich10 Studien
- COPD9 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.